# Single-Molecule Multi-Agonists vs Combination Therapy: Pros and Cons

Canonical source: https://retacompare.com/research/single-molecule-multi-agonists-vs-combination-therapy-pros-and-cons

Receptor Pharmacology · 2026-05-02


    This article explores the advantages and disadvantages of single-molecule multi-agonists versus combination therapies in the context of obesity and metabolic disorders, particularly following the advancements seen with Retatrutide in clinical trials.

The big picture

As the field of obesity and metabolic disorder treatments evolves, the introduction of multi-agonist therapies like Retatrutide (LY3437943) is reshaping the landscape. Currently in Phase 3 clinical trials, Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. This innovative approach raises critical questions about the efficacy and practicality of single-molecule multi-agonists compared to traditional combination therapies, such as CagriSema, which combines cagrilintide (an amylin analog) with semaglutide (a GLP-1 receptor agonist). The ongoing research aims to clarify which method may provide superior outcomes for patients struggling with obesity and related metabolic conditions.

How it works

The pharmacological rationale behind multi-agonists lies in their ability to simultaneously activate multiple pathways that regulate appetite, glucose metabolism, and energy expenditure. For example, Retatrutide's triple agonism is designed to leverage the synergistic effects of GLP-1, GIP, and glucagon. GLP-1 is known for its role in enhancing insulin secretion and promoting satiety, while GIP contributes to insulin sensitivity and fat metabolism. Glucagon, on the other hand, plays a crucial role in energy expenditure and gluconeogenesis. The combination of these mechanisms in a single molecule aims to provide a more comprehensive approach to obesity management than dual agonists like Tirzepatide, which targets GLP-1 and GIP, or other dual therapies such as Mazdutide and Survodutide.

Key points at a glance

Retatrutide is a triple agonist currently in Phase 3 trials and is not yet FDA-approved.

Tirzepatide is an approved dual GLP-1/GIP agonist, while semaglutide is a GLP-1 mono-agonist.

Combination therapies like CagriSema leverage different mechanisms by co-administering separate drugs.

Multi-agonists may offer more streamlined dosing and potentially improved patient adherence.

Current research is focused on understanding the long-term efficacy and safety of these therapies.

There are no approved quad-agonist or penta-agonist therapies, with ongoing research in early clinical stages.

Where this fits in the pipeline

As of October 2023, the landscape for obesity and metabolic disorder treatments is vibrant, with several promising candidates in various stages of development. Retatrutide, developed by Lilly, is leading the charge in multi-agonist therapies. In contrast, combination therapies like CagriSema are being explored by Novo Nordisk, highlighting the dual approach to weight management. Other notable candidates include Mazdutide (Innovent), Survodutide (Boehringer), and Pemvidutide (Altimmune), which represent the ongoing interest in dual agonism. The pipeline remains dynamic, with many programs still in preclinical or early clinical stages.

What it could mean for patients

If successful, multi-agonist therapies like Retatrutide could provide a new option for patients with obesity, potentially leading to enhanced weight loss and improved metabolic profiles. The simultaneous targeting of multiple receptors may offer a more holistic approach to treatment, addressing the multifactorial nature of obesity. However, the clinical impact remains to be fully elucidated, particularly regarding long-term safety and efficacy. It is crucial for ongoing studies to carefully evaluate these factors to ensure that new therapies provide meaningful benefits to patients.

Open questions and what we don't yet know

Despite the promise of multi-agonist therapies, several questions remain unanswered. The long-term effects of these treatments on weight maintenance, metabolic health, and safety profiles are still under investigation. Additionally, the complexity of receptor interactions raises concerns about potential side effects and the need for precise dosing strategies. Regulatory hurdles also remain, as no quad-agonist or penta-agonist therapies have been approved, which may influence the pace of development for these innovative treatment options.

Bottom line

With the advent of multi-agonist therapies like Retatrutide, the treatment landscape for obesity is evolving. Ongoing research will be critical in determining the most effective strategies, whether through single-molecule multi-agonists or combination therapies.

This article is research-only educational content and is not medical advice. None of the drugs discussed are approved as quad-agonists or penta-agonists at the time of writing.

## Sources